Navigation Links
Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
Date:10/3/2007

SAN MATEO, Calif., Oct. 3 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing anti-inflammatory therapeutics for chronic and acute inflammatory diseases, announced today the completion of enrollment and patient dosing in its Phase II clinical study of its lead compound, A-002 for stable coronary artery disease. Data analysis is scheduled to be completed by the end of the year.

"We are pleased with the rapid enrollment of this study and look forward to reporting the results later this year," said Colin Hislop, M.D., Senior Vice President Clinical Development at Anthera Pharmaceuticals. "Previously reported results have been promising and we expect the results of our ongoing evaluation will help guide Phase III clinical trial design."

A-002 Clinical Trial Protocol

The PLASMA trial (Phospholipase Levels And Serological Markers of Atherosclerosis) is a multi-center, randomized, double-blind, placebo-controlled trial that enrolled approximately 400 patients with stable coronary heart disease. Subjects were randomized to receive four doses of A-002 or standard of care for up to eight weeks. The study was designed to investigate the safety and the efficacy of A-002 (a potent inhibitor of the human enzymes known as secretory phospholipase A2) on dyslipidemia (primarily Low Density Lipoprotein Cholesterol "LDL-C") and systemic inflammation (as measured by levels of C-Reactive Protein "CRP") in patients with stable coronary heart disease. Elevated levels of sPLA2 have been implicated in abnormal lipid metabolism, atherogenesis and vascular inflammation. The Company is scheduled to meet with the Food and Drug Administration in the fourth quarter for an end-of-Phase II meeting to obtain concurrence on the design of the Phase III program.

A-002 Once Daily Clinical Trial

Based on preliminary data from the PLASMA Phase II clinical trial, Anthera has initiated a follow up clinical study investigat
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015  ResMed Inc. (NYSE: RMD ) today announced ... the quarter was $423.0 million, a 10 percent increase compared ... increase on a constant currency basis). Net income was $91.2 ... ended December 31, 2013. Diluted earnings per share for the ...
(Date:1/22/2015)... DIEGO , Jan. 22, 2015  Profil Institute for ... on diabetes and obesity, announced today a new textbook,  ... Development,  published by Springer, a leading global scientific publisher. ... analyze and illustrate techniques for use in early phase ...
(Date:1/22/2015)... Jan. 22, 2015 Research and Markets ( http://www.researchandmarkets.com/research/w25xpc/allergy ... Market by Allergen Source, Product & by End User - ... The global allergy diagnostics market is valued at ... a CAGR of 12.67%, to reach $2,230.72 million by 2019. ...
Breaking Medicine Technology:ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 2Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 3
... ZANESVILLE, Ohio , May 12 Huntington Bank ... unique funding model to finance a $25 million ... region,s largest health care providers, Zanesville -based Genesis HealthCare ... install a clinical information system enabling Genesis to establish an ...
... ,, NEW YORK , May 12 Reportlinker.com announces that a new market ... , Antifungal Drugs: Technologies and ... http://www.reportlinker.com/p0196570/Antifungal-Drugs-Technologies-and-Global-Markets.html , ... , , , ...
Cached Medicine Technology:Huntington Financing Package Supports Major Regional Medical Center Electronic Medical Records Project 2Reportlinker Adds Antifungal Drugs: Technologies and Global Markets 2Reportlinker Adds Antifungal Drugs: Technologies and Global Markets 3Reportlinker Adds Antifungal Drugs: Technologies and Global Markets 4Reportlinker Adds Antifungal Drugs: Technologies and Global Markets 5Reportlinker Adds Antifungal Drugs: Technologies and Global Markets 6Reportlinker Adds Antifungal Drugs: Technologies and Global Markets 7Reportlinker Adds Antifungal Drugs: Technologies and Global Markets 8Reportlinker Adds Antifungal Drugs: Technologies and Global Markets 9Reportlinker Adds Antifungal Drugs: Technologies and Global Markets 10Reportlinker Adds Antifungal Drugs: Technologies and Global Markets 11Reportlinker Adds Antifungal Drugs: Technologies and Global Markets 12Reportlinker Adds Antifungal Drugs: Technologies and Global Markets 13Reportlinker Adds Antifungal Drugs: Technologies and Global Markets 14
(Date:1/22/2015)... (PRWEB) January 23, 2015 The U.S. ... R.Ph., DICVP, Director of Clinical Pharmacy Services at North ... the recipient of the 2015 Beal Award for Distinguished ... USP has relied on the contributions of volunteer experts ...
(Date:1/22/2015)... The City of West Hollywood hosted a news conference on Thursday, ... of the Supreme Court decision Roe v. Wade, which legalized abortion ... Roe vs. Wade decision and the fight to protect a women’s ... of West Hollywood Councilmember Abbe Land. “We need to continue to ...
(Date:1/22/2015)... 2015 Padre Murphy's and Owner Tom Boyle ... Pro Player Health Alliance (PPHA). The PPHA's passion for ... everyone, including NFL greats, treated for obstructive sleep apnea (OSA) ... supporting the cause in the valley. The most recent plans ...
(Date:1/22/2015)... a famous wedding dress company offering many trendy designs. Today, ... Twitter, and Pinterest. The fans will have an opportunity to ... week. , Moreover, the company has extended its 2015 New ... for more information. , Angelweddingdress is a famous ...
(Date:1/22/2015)... New York (PRWEB) January 22, 2015 The ... ) in the U.S. District Court, Southern District of West ... Bard, Inc. in that proceeding’s first bellwether trial. In an ... for a new trial after finding that C.R. Bard had ...
Breaking Medicine News(10 mins):Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 2Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 3Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 4Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4
... Calling for Fair WagesBUFFALO, N.Y., April 24 Hundreds ... for a rally in front of Buffalo,s city hall ... (EMTs) who are calling for fair wages from the ... contract with the city of Buffalo. However, the company ...
... INSTITUTE, W.Va., April 24 Bayer CropScience is pleased ... the Emergency Services Leader for the Institute site. In ... at the Institute site and will be the primary ... (Photo: http://www.newscom.com/cgi-bin/prnh/20090424/NE04976 ...
... yet know if the virus is the same that sickened ... News) -- Mexican officials took extraordinary steps Friday to try ... least 16 people, and possibly dozens more, and sickened more ... officials worried that it could mark the start of a ...
... Smith & Nephew NPWT to be Presented at Symposium on ... & Nephew Inc,s (LSE: SN; NYSE: SNN ) ... featuring its Negative Pressure Wound Therapy (NPWT) products will be ... and Wound Healing Society Meeting. The poster session is ...
... April 24 Leading herbalist and elephantjournal columnist ... Is this old school preventative measure doing more ... and eat for oral health? Waylon Lewis, editor-in-chief ... , and contributor to the Huffington Post ( ...
... patients, financial responsibility for their diabetes therapy, positively ... in real time at point of dispensing ACCU-CHEK(R) ... the launch of its new eVoucherRx(TM) pilot program ... patients with diabetes to receive their co-pay savings ...
Cached Medicine News:Health News:Bayer CropScience Welcomes New Emergency Services Leader to the Institute Site 2Health News:At Least 16 Dead, Hundreds Ill in Swine Flu Outbreak in Mexico 2Health News:At Least 16 Dead, Hundreds Ill in Swine Flu Outbreak in Mexico 3Health News:New Evidence Supports Efficacy and Value of Smith & Nephew NPWT Products 2Health News:New Evidence Supports Efficacy and Value of Smith & Nephew NPWT Products 3Health News:New Evidence Supports Efficacy and Value of Smith & Nephew NPWT Products 4Health News:elephantjournal.com: Is Fluoridating Waters Giving Kids Cavities? 2Health News:Roche Announces New Co-pay Program in Florida that Makes It Easier for Patients with Diabetes to Receive Savings on ACCU-CHEK(R) Blood Glucose Test Strips 2Health News:Roche Announces New Co-pay Program in Florida that Makes It Easier for Patients with Diabetes to Receive Savings on ACCU-CHEK(R) Blood Glucose Test Strips 3
The BUN method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of urea nitrogen in serum, plasma and urine....
For the quantitative in vitro determination of Urea in serum, plasma or urine....
For the quantitative in vitro determination of Triglycerides in serum and plasma....
The CKMB method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of creatine kinase MB isoenzyme activity in serum and plasma...
Medicine Products: